Sunday, May 15, 2022

FDA refuses Novo Nordisk’s once-weekly semaglutide

Novo Nordisk has received a refusal to file letter from the US Food and Drug Administration (FDA) for a label expansion application for semaglutide.

The application, filed on 20 January 2021, is seeking an expanded approval for once-weekly semaglutide 2.0mg for the treatment of type 2 diabetes.

In a statement, Novo said that the FDA has requested additional information, including data relating to a proposed new manufacturing site, in its letter.

The company added that it believes the already completed clinical trial programme will be ‘sufficient’ for approval of the label expansion application.

The FDA initially approved oral semaglutide under the brand name Rybelsus in September 2019, making it the first glucagon-like peptide (GLP-1) receptor protein treatment approved in the US that does not need to be injected.

Novo is expecting to resubmit the application for once-weekly semaglutide to the FDA in the second quarter of 2021.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...